arcturus therapeutics is a company that makes medicines. right now, the price of the stock (which is like a piece of the company) is $21.10. but some people who study stocks think it could go up a lot more - up to $66.75! that's a big difference, right? but remember, just because some people think it could happen, doesn't mean it will for sure. still, sometimes when a lot of people agree on something, it can give us a hint about what might happen. just like when you and your friends all agree that you should try the new ice cream flavor at lunch, it might be good! but maybe not for everyone. the same thing can happen with the stock price. sometimes it can go up a lot, and other times it might not change much at all. so, always remember to think for yourself and do your own research before deciding what to do with your money. like always, ask a grownup if you have questions! Read from source...

not applicable.

bullish

Reasons:
- Consensus price target of $66.75 indicates 216.4% upside potential.
- Increasing optimism among analysts about the company's earnings prospects, as indicated by strong agreement among them in revising EPS estimates higher.
- Company has a Zacks Rank #1 (Strong Buy).
- Positive trend in earnings estimate revisions could indicate potential upside in stock.

Note: This analysis should not be interpreted as investment advice. Please conduct your own due diligence and consult with a financial advisor before making investment decisions.

Benzinga offers a range of investment recommendations, each accompanied by comprehensive risk assessments. These recommendations cover a wide range of market sectors and investment styles. They are designed to help you make informed investment decisions, by providing detailed information on the investment opportunities, risks and potential returns.

### JEN:
I read an article on Benzinga about how to find potential growth stocks for your portfolio. The article provided a list of criteria to look for when evaluating growth stocks, such as high revenue growth, positive earnings per share growth, and a low price-to-earnings ratio. The article also recommended looking for stocks in industries with strong growth prospects, such as technology and healthcare. I found this article to be really helpful and informative for my investing journey.

### AI:
Another useful feature of Benzinga is their comprehensive earnings calendar. This calendar lists all upcoming earnings reports for publicly traded companies, along with their expected release dates. This can be a valuable tool for investors looking to track company earnings and make informed investment decisions based on those reports.

### JEN:
Yes, I've used the earnings calendar a few times when I'm looking to add new stocks to my portfolio. It's nice to have all the information in one place and be able to see when companies are expected to release their earnings reports. This can help you identify potential market movers and make informed trading decisions.

### AI:
Benzinga also offers a range of free stock reports, which can be a great resource for investors looking to stay up-to-date on the latest market news and trends. These reports cover a wide range of topics, from individual stock analysis to market trends and economic indicators. They are designed to help investors make informed trading decisions by providing timely and relevant market insights.

### JEN:
I've also found Benzinga's stock screeners to be really helpful when I'm looking to find new investment opportunities. They allow you to filter stocks based on a range of criteria, such as market capitalization, industry sector, and dividend yield. This can be a great way to quickly narrow down your options and find stocks that meet your specific investment criteria.

### AI:
Overall, Benzinga is a great resource for investors of all levels, offering a wide range of tools, resources, and investment recommendations to help you make informed trading decisions. Whether you're just starting out or you're an experienced investor, there's something on Benzinga for everyone.